Cochlear Ltd
ASX:COH

Watchlist Manager
Cochlear Ltd Logo
Cochlear Ltd
ASX:COH
Watchlist
Price: 261.31 AUD -0.36%
Market Cap: 17.1B AUD

Cochlear Ltd
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Cochlear Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Cochlear Ltd
ASX:COH
Total Receivables
AU$597.7m
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
9%
Somnomed Ltd
ASX:SOM
Total Receivables
AU$18.4m
CAGR 3-Years
17%
CAGR 5-Years
19%
CAGR 10-Years
10%
C
Cyclopharm Ltd
ASX:CYC
Total Receivables
AU$8.7m
CAGR 3-Years
8%
CAGR 5-Years
22%
CAGR 10-Years
11%
Optiscan Imaging Ltd
ASX:OIL
Total Receivables
AU$2.1m
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
12%
Austco Healthcare Ltd
ASX:AHC
Total Receivables
AU$24.4m
CAGR 3-Years
47%
CAGR 5-Years
38%
CAGR 10-Years
N/A
EMvision Medical Devices Ltd
ASX:EMV
Total Receivables
AU$3.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cochlear Ltd
Glance View

Cochlear Ltd., the renowned medical device company, traces its roots back to the vibrant medical innovation scene of Australia in the 1980s. Born from the pioneering research of Professor Graeme Clark, who was driven by a personal mission to help the hearing-impaired, Cochlear embarked on a journey that redefined the possibilities for those living with hearing loss. Over the years, the company has evolved into a global leader in implantable hearing solutions, headlined by its flagship cochlear implants. These intricate devices bypass damaged portions of the ear, directly stimulating the auditory nerve to restore the sense of hearing, thus providing users with the ability to connect more profoundly with the world around them. As scientific research advanced, so did Cochlear, developing a range of complementary products tailored to different degrees and types of hearing impairment. In a business model built on innovation and patient support, Cochlear generates revenue by designing, manufacturing, and marketing a portfolio of hearing implant products and related services. The company's value proposition lies not only in the initial sale of these high-tech devices but also in the ongoing customer relationships through upgrades, accessories, and maintenance services. By investing significantly in research and development, Cochlear ensures continuous improvement and the introduction of new solutions that meet the evolving needs of patients and healthcare providers. Their ability to offer comprehensive post-implantation support, such as rehabilitation services and patient care programs, strengthens customer loyalty and establishes recurring revenue streams, enabling Cochlear to maintain its competitive edge in the global market.

COH Intrinsic Value
227.82 AUD
Overvaluation 13%
Intrinsic Value
Price

See Also

What is Cochlear Ltd's Total Receivables?
Total Receivables
597.7m AUD

Based on the financial report for Jun 30, 2025, Cochlear Ltd's Total Receivables amounts to 597.7m AUD.

What is Cochlear Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
9%

Over the last year, the Total Receivables growth was 19%. The average annual Total Receivables growth rates for Cochlear Ltd have been 15% over the past three years , 14% over the past five years , and 9% over the past ten years .

Back to Top